Introduction
The clinical interest in the physiological importance of the steroid hormone vitamin D and its possible roles in the pathophysiological processes of many diseases have increased the demand for the measurement of vitamin D and its metabolites (1) . On the one hand, vitamin D deficiency results in abnormalities in bone metabolism known as rickets, osteomalacia, and osteoporosis (2, 3) . On the other hand, it is associated with non-skeletal diseases such as type one diabetes mellitus (2, 4, 5) , multiple sclerosis (2), cancer (2, 5) , hypertension (5) or cardiovascular disease (5, 6 ).
In the liver vitamin D is converted to the 25-hydroxy-vitamin D (25[OH]D) and transported in the circulation by the vitamin-D binding protein (DBP).
In the kidneys the biologically active form 1,25-dihydroxy-vitamin D (1, 25 [OH]2D) is created from 25(OH)D (7) . This active form has a circulating halflife of only 4-6 hours and serum-levels of about 1000 fold less than 25(OH)D (1, 8, 9) . The major circulating form of vitamin D is 25(OH)D, which has a half-life of approximately 2-3 weeks (8) . Therefore, the total 25(OH)D is principally used as the biomarker indicating the vitamin D status (9, 10) .
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In the past, 25(OH)D measurements have proven to be a major challenge with a wide spread variation in the results (1) . The sometimes huge between-method discrepancies have been known for many years from data obtained from the International Vitamin D External Quality Assessment Scheme (DEQAS) (11) (12) (13) . The DEQAS was already founded in 1989 and meanwhile has become the largest vitamin D quality assessment program worldwide (14) .
To overcome the problem of inter-laboratory as well as inter-assay discrepancies, munoassays. According to the protocol (17) , equal parts of the high-and low-level QC material were mixed to create the mid-level. At least one run per day at five consecutive workdays (from monday to friday) with a specific sequence (mid-, high-, low-, mid-, mid-, low-, low-, high-, high-, and mid-level) without change, interruption or intervening samples was analyzed for each immunoassay to determine the between-run precision (N = 5) for each level. In addition to the required measurements in the EP10-A2 protocol, one tenfold measurement (N = 10) of the low-, mid-and high-level of each immunoassay was performed at one day to determine the within-run precision.
Materials and methods

Subjects
Precision studies of the LC-MS/MS method
The precision studies of the LC-MS/MS method were performed according to the Guidance for Industry -Bioanalytical Method Validation (18) . 
Statistical analysis
Bland-Altman and Deming regression plots were calculated for methods comparison of all tested 25(OH)D assays. The LC-MS/MS method was defined as the reference method. All other methods were compared to the reference method. Withinrun and between-run precision at each concentration level were assessed by calculating the mean, the standard deviation (SD) and the coefficient of variation (CV) of the above mentioned replicates and sequences. The CV was calculated based on the formula: CV (%) = 100 x standard deviation (SD)/mean (ng/mL). According to the literature (18), the precision goal for each concentration level for the within-run and between-run was not to exceed 20% of the CV. Analyse-it® software version 2.30 (Analyse-it Software, Ltd, Leeds, United Kingdom) was used for statistical analysis. A P-value < 0.05 was considered statistically significant.
Results
Characteristics of the study population
The study population mainly consisted of adults and a total of five adolescents between 15 and 19 years. No newborns or young children were measured. Of all patients (N = 198), 57.6% (N = 114) were female. The median age was 63 (range: 15-91) years.
Immunoassays vs. LC-MS/MS method
Bland-Altman plots are illustrated in Figure 1 
Precision studies of the immunoassays
The results of the precision studies of the immunoassays are demonstrated in Table 1 . All immunoassays showed a within-run and between-run imprecision of ≤ 20% at each concentration level (low, mid, high). The highest within-run CV (19.0%) was observed at the low-level precision measurements with the IDS-iSYS 25(OH)D S assay. The highest between-run CV (19.1%) was shown at the lowlevel precision measurements with the IDS-iSYS 25(OH)D assay. 
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Precision studies of the LC-MS/MS method
The results of the precision studies of the LC-MS/ MS method are shown in 
25(OH)D 2 and C 3 -epimer detection by the LC-MS/MS method
In all blood samples (N = 198), no 25(OH)D 2 and no C 3 -epimer were detected with the LC-MS/MS method.
Discussion
The (21) . Meanwhile the manufacturer has withdrawn this assay from the market. High inter-assay disagreement in the 25(OH)D measurements (20, 22) can lead to an underestimation (23) or overestimation (24) of the 25(OH)D serum-levels. The lack of standardization, matrix effects, poor antibody specificity, and cross-reactivity with other 25(OH)D metabolites could be possible reasons for reported high inter-assay disagreement before standardization (21) .
The C 3 -epimer is one of the vitamin D metabolites, which is considered to be a potential confounder in 25(OH)D measurements, especially in infants (16) . In the present study, no newborns or young children were included. Although the C 3 -epimer is also described in adults (25, 26) , no C 3 -epimer was detected with the LC-MS/MS method.
Not only the C 3 -epimer but also other vitamin D metabolites are considered as possible reasons for significant inter-assay differences of previous published 25 (9, 29) . A low batch-to-batch variation and a low limit of detection are further advantages of this method (30) . In the present study, we used an LC-MS/MS method, which has met the performance target set by the international DEQAS Advisory Panel in 2013 and 2014 (data not shown). The method was aligned to the NIST SRM 972a and enabled the separation and qualitative detection of the C 3 -epimers in a single analytical run. Nevertheless the biggest problem in 25(OH)D measurements in the last few years was the lack of a common standard. Furthermore not all LC-MS/ MS methods used in previous comparative studies (20) could separate C 3 -epimers. The LC-MS/MS method in particular was recommended to be aligned to the NIST SRM and to be able to discriminate the C 3 -epimer (10, 20) . The strength of this study is that these recommendations of the VSDP have been completely fulfilled. The reported new generation of 25(OH)D assays (except the previous used IDS-iSYS 25 [OH]D assay) tested are aligned to the NIST SRM 2972 or 972a.
The limitation of this study is that the precision studies of the immunoassays and the precision studies of the LC-MS/MS method were not performed with the same protocol. Therefore, the within-run and between-run precision measurements of the immunoassays are not comparable with the LC-MS/MS method.
In conclusion, the new generation of the NIST SRM aligned immunoassays and LC-MS/MS evaluated in this study are useful methods for measuring 25(OH)D serum-levels in clinical laboratories. The performance characteristics are suitable for routine diagnostic purposes.
